Stockreport

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease [Yahoo! Finance]

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF OSAKA, Japan & CAMBRIDGE, Mass., April 18, 2024 BUSINESS WIRE )--Takeda TSE:4502/NYSE:TAK today announced that the U.S. Food and Drug Administration (FDA) has approved [Read more]